collection
MENU ▼
Read by QxMD icon Read
search

transplantation

shared collection
8 papers 0 to 25 followers
https://www.readbyqxmd.com/read/26558185/biomarkers-in-kidney-transplantation-from-bench-to-bedside
#1
Natavudh Townamchai, Somchai Eiam-Ong
Immunosuppressive drug level monitoring and serum creatinine are widely used for kidney transplantation (KT) monitoring. Monitoring of drug level is not the direct measurement of the immune response while the rising of creatinine is too late for detection of allograft injury. Kidney biopsy, the gold standard for KT monitoring, is invasive and may lead to complications. Many biomarkers have been discovered for direct monitoring of the immune system in KT and the benefit of some biomarkers has reached clinical level...
November 6, 2015: World Journal of Nephrology
https://www.readbyqxmd.com/read/24484750/transplanted-kidney-function-evaluation
#2
REVIEW
Ayşe Aktaş
The best option for the treatment of end-stage renal disease is kidney transplantation. Prompt diagnosis and management of early posttransplantation complications is of utmost importance for graft survival. Biochemical markers, allograft biopsies, and imaging modalities are used for the timely recognition and management of graft dysfunction. Among several other factors, improvements in imaging modalities have been regarded as one of the factors contributing to increased short-term graft survival. Each imaging procedure has its own unique contribution to the evaluation of renal transplant dysfunction...
March 2014: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/24568687/cytomegalovirus-glomerulopathy-and-cytomegalovirus-interstitial-nephritis-on-sequential-transplant-kidney-biopsies
#3
Alfred A Vichot, Richard N Formica, Gilbert W Moeckel
Cytomegalovirus (CMV) nephropathy may be seen in kidney transplant biopsy specimens. We report a CMV-negative patient who received a kidney transplant from a CMV-positive donor and subsequently developed CMV glomerulopathy and CMV-associated interstitial nephritis, as observed in 2 sequential kidney biopsies. The first biopsy specimen showed CMV-positive endothelial cells in glomerular capillaries and CMV-infected monocytes in glomerular capillary lumens. The second biopsy specimen showed CMV-positive cells in the interstitium with associated lymphoplasmacytic infiltrate and tubular injury, but no evidence of direct CMV infection in tubular epithelial cells...
March 2014: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/20688115/towards-graft-specific-immune-suppression-gene-therapy-of-the-transplanted-kidney
#4
REVIEW
Maria Sandovici, Leo E Deelman, Ariela Benigni, Robert H Henning
Kidney transplantation remains the best therapeutic option for patients with end-stage renal disease. Immunosuppressive therapy has largely resolved the issue of acute transplant rejection. However, because of its systemic nature, immunosuppressive therapy trades off efficacy against side-effects and its chronic use has been associated with severe infections and malignancy. Moreover, long-term survival of renal grafts did not change over the past twenty years. This situation may be improved by using gene therapy as an alternative or add-on strategy to the classic, systemic immune suppression...
November 30, 2010: Advanced Drug Delivery Reviews
https://www.readbyqxmd.com/read/22914685/biomarkers-in-native-and-transplant-kidneys-opportunities-to-improve-prediction-of-outcomes-in-chronic-kidney-disease
#5
REVIEW
Sacha A De Serres, Jay C Varghese, Adeera Levin
PURPOSE OF REVIEW: Predicting the outcomes of patients with chronic kidney disease (CKD) is important from both patient and healthcare system perspectives. This review examines the current state of conventional and nonconventional biomarkers as noninvasive tools to improve risk-stratification and outcome prediction in CKD. RECENT FINDINGS: Conventional biomarkers (serum creatinine, urine albumin, and clinical variables such as sex, age, and diabetes) have been the cornerstone of most prediction models for CKD progression to end-stage renal disease (ESRD), and adverse cardiovascular outcomes including death...
November 2012: Current Opinion in Nephrology and Hypertension
https://www.readbyqxmd.com/read/23474011/recurrent-proliferative-glomerulonephritis-with-monoclonal-igg-deposits-of-igg2%C3%AE-subtype-in-a-transplanted-kidney-a-case-report
#6
Keiichi Sumida, Yoshifumi Ubara, Yuji Marui, Michio Nakamura, Kenmei Takaichi, Shinji Tomikawa, Takeshi Fujii, Kenichi Ohashi
Proliferative glomerulonephritis with monoclonal immunoglobulin G (IgG) deposits (PGNMID) is a recently described disease entity. In the kidney transplantation literature, only 6 recurrent and 2 de novo PGNMID cases, including 7 of the IgG3 subclass (6 with κ light chain and 1 with λ light chain) and 1 of the IgG1 subclass (λ light chain), have been described to date. We describe a 52-year-old man with end-stage renal disease whose primary glomerular disease had been suggested to be membranoproliferative glomerulonephritis...
September 2013: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/26422506/clinical-and-molecular-significance-of-microvascular-inflammation-in-transplant-kidney-biopsies
#7
Anjali Gupta, Pilib Ó Broin, Yi Bao, James Pullman, Layla Kamal, Maria Ajaimy, Michelle Lubetzky, Adriana Colovai, Daniel Schwartz, Graciela de Boccardo, Aaron Golden, Enver Akalin
The diagnostic criteria for antibody-mediated rejection (AMR) are continuously evolving. Here we investigated the clinical and molecular significance of different Banff microvascular inflammation (MVI) scores in transplant kidney biopsies. A total of 356 patients with clinically indicated kidney transplant biopsies were classified into three groups based on MVI scores of 0, 1, 2, or more for Groups 1-3, respectively. Gene expression profiles were assessed using arrays on a representative subset of 93 patients...
January 2016: Kidney International
https://www.readbyqxmd.com/read/27288461/should-belatacept-be-the-centrepiece-of-renal-transplantation
#8
Monika Huber, Stephan Kemmner, Lutz Renders, Uwe Heemann
Belatacept was developed to minimize cardiovascular risk and nephrotoxicity associated with calcineurin inhibitor (CNI)-based immunosuppression. Recently, 7-year data from the Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT), a phase III study comparing belatacept with cyclosporine, have been published. While during the first year of belatacept the risk of acute rejection episodes was elevated, this seemingly had marginal consequences for long-term graft survival and function as well as patient survival...
June 10, 2016: Nephrology, Dialysis, Transplantation
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"